Patents by Inventor Jianmei Kochling

Jianmei Kochling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230172903
    Abstract: The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
    Type: Application
    Filed: July 14, 2022
    Publication date: June 8, 2023
    Inventors: Hanlan LIU, Chris WILLIS, Renu BHARDWAJ, Jianmei KOCHLING, Judith PETERSCHMITT, Craig SIEGEL
  • Patent number: 11458119
    Abstract: The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: October 4, 2022
    Assignee: GENZYME CORPORATION
    Inventors: Hanlan Liu, Chris Willis, Renu Bhardwaj, Jianmei Kochling, Craig Siegel
  • Publication number: 20210393590
    Abstract: The hemitartrate salt of a compound represented by the following structural formula: (Formula 1 Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
    Type: Application
    Filed: September 3, 2021
    Publication date: December 23, 2021
    Inventors: Hanlan LIU, Chris WILLIS, Renu BHARDWAJ, Diane P. COPELAND, Abizer HARIANAWALA, Jeffrey SKELL, John MARSHALL, Jianmei KOCHLING, Gerard PALACE, Judith PETERSCHMITT, Craig SIEGEL, Seng CHENG
  • Publication number: 20210369672
    Abstract: The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
    Type: Application
    Filed: January 7, 2021
    Publication date: December 2, 2021
    Inventors: Hanlan LIU, Chris WILLIS, Renu BHARDWAJ, Diane P. COPELAND, Abizer HARIANAWALA, Jeffrey SKELL, John MARSHALL, Jianmei KOCHLING, Gerard PALACE, Judith PETERSCHMITT, Craig SIEGEL, Seng CHENG
  • Publication number: 20160166542
    Abstract: The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
    Type: Application
    Filed: February 22, 2016
    Publication date: June 16, 2016
    Inventors: Hanlan Liu, Chris Willis, Renu Bhardwaj, Diane P. Copeland, Abizer Harianawala, Jeffrey Skell, John Marshall, Jianmei Kochling, Gerard Palace, Judith Peterschmitt, Craig Siegel, Seng Cheng
  • Publication number: 20160120842
    Abstract: The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
    Type: Application
    Filed: January 13, 2016
    Publication date: May 5, 2016
    Inventors: Hanlan Liu, Chris Willis, Renu Bhardwaj, Diane P. Copeland, Abizer Harianawala, Jeffrey Skell, John Marshall, Jianmei Kochling, Gerard Palace, Judith Peterschmitt, Craig Siegel, Seng Cheng
  • Publication number: 20130137743
    Abstract: The hemitartrate salt of a compound represented by the following structural formula: (Formula I Hemitartrate), which may be used in pharmaceutical applications, are disclosed. Particular single crystalline forms of the Formula (I) Hemitartrate are characterized by a variety of properties and physical measurements. As well, methods of producing crystalline Formula (I) Hemitartrate, and using it to inhibit glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat a number of diseases, are also discussed. Pharmaceutical compositions are also described.
    Type: Application
    Filed: November 24, 2010
    Publication date: May 30, 2013
    Applicant: GENZYME CORPORATION
    Inventors: Hanlan Liu, Chris Willis, Renu Bhardwaj, Diane P. Copeland, Abizer Harianawala, Jeffrey Skell, John Marshall, Jianmei Kochling, Gerard Palace, Judith Peterschmitt, Craig Siegel, Seng Cheng